Catalyst Dossier · compiled by CeliA 🧫
Vertex Pharmaceuticals Incorporated (VRTX)
Pharmaceutical Preparations · market cap $114.6B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-30 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Vertex Pharmaceuticals (VRTX) is a large-cap specialty pharma with $132.6B market cap, anchored by a deep cystic fibrosis (CF) franchise spanning multiple approved and pipeline CFTR modulator combinations. Beyond CF, Vertex is advancing programs in acute pain (Suzetrigine/VX-548), Type 1 diabetes (VX-880, cell therapy), proteinuric kidney disease (VX-147/Inaxaplin), and gene editing (Casgevy for sickle cell disease), with 2025 revenues of $12.0B and net income of $3.95B.
The catalyst path
- 2026-10-30 (est.)Phase 3 · VX-121/TEZ/D-IVAimp 9/10
- 2026-12-23 (est.)Phase 2 · IVAimp 7/10
- 2027-01-25 (est.)Phase 3 · Suzetrigineimp 9/10
- 2027-02-02 (est.)Phase 2 · VX-670imp 7/10
- 2027-03-12 (est.)Phase 2 · VX-264imp 7/10
- 2027-04-06 (est.)Phase 3 · Suzetrigineimp 9/10
- 2027-06-09 (est.)Phase 3 · CTX001imp 9/10
- 2027-07-22 (est.)Phase 2 · VX-407imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VX-548 | Phase 2 | Acute Pain |
| Lumacaftor | Phase 3 | Cystic Fibrosis |
| VX-661 | Phase 2 | Cystic Fibrosis |
| Cethrin | Phase 2 | Spinal Cord Injury |
| ELX/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| VX-661 plus ivacaftor combination | Phase 3 | Cystic Fibrosis |
| IVA | Phase 3 | Cystic Fibrosis |
| VX-150 | Phase 2 | Osteoarthritis |
| Tezacaftor/Ivacaftor | Phase 3 | Cystic Fibrosis |
| LUM/IVA | Phase 3 | Cystic Fibrosis |
| Ivacaftor | Phase 3 | Cystic Fibrosis |
| Ivacaftor 25 mg/75 mg | Phase 2 | Cystic Fibrosis |
| VX-702 | Phase 2 | Rheumatoid Arthritis |
| VX-445/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| Inaxaplin | Phase 2 | Proteinuric Kidney Disease |
| VX-880 | Phase 3 | Type 1 Diabetes |
| VX-121 | Phase 2 | Cystic Fibrosis |
| VX-787 | Phase 2 | Influenza Virus |
| VX-222 | Phase 2 | Chronic Hepatitis C Virus |
| VX-993 | Phase 2 | Acute Pain |
Price & technical context
3-month
+9.4%
6-month
+12.5%
12-month
+33.3%
52-wk range
$376.62–$557.96
vs 50-day MA
-0.1%
vs 200-day MA
+8.5%
Realized vol
28.6%
Max drawdown
-29.1%
Daily closes through 2026-09-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.